The Risky Business of Drug Development- The Final Say of National Hta Agencies on A Pharmaceutical's Benefit During The Last Stretch of An Expensive, Long-Lasting And Arduous Development Journey – As Illustrated By The Decisions Of Germany' ...
Abstract
Authors
A. Maetzel T.R. Staab J. Ruof